GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Price-to-Owner-Earnings

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Price-to-Owner-Earnings : (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Price-to-Owner-Earnings?

As of today (2024-04-27), Calliditas Therapeutics AB's share price is $19.5006. Calliditas Therapeutics AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Calliditas Therapeutics AB's Price-to-Owner-Earnings or its related term are showing as below:


CALT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-27), Calliditas Therapeutics AB's share price is $19.5006. Calliditas Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.95. Therefore, Calliditas Therapeutics AB's PE Ratio for today is At Loss.

As of today (2024-04-27), Calliditas Therapeutics AB's share price is $19.5006. Calliditas Therapeutics AB's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.95. Therefore, Calliditas Therapeutics AB's PE Ratio without NRI for today is At Loss.

During the past 9 years, Calliditas Therapeutics AB's highest PE Ratio without NRI was 92.26. The lowest was 0.00. And the median was 80.44.


Calliditas Therapeutics AB Price-to-Owner-Earnings Historical Data

The historical data trend for Calliditas Therapeutics AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Price-to-Owner-Earnings Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calliditas Therapeutics AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, Calliditas Therapeutics AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calliditas Therapeutics AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Price-to-Owner-Earnings falls into.



Calliditas Therapeutics AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Calliditas Therapeutics AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=19.5006/-1.77
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (NAS:CALT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Calliditas Therapeutics AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.